Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease

Abstract

Objective

Stenting of the iliac veins is increasingly considered in the presence of symptomatic obstructive chronic lesions in the iliac vein segment. However, it is often necessary to extend the stented zone into the inferior vena cava, increasing the risk of contralateral iliac vein thrombosis. This study aims to review the current literature concerning the incidence of contralateral deep vein thrombosis after stenting across the iliocaval confluence.

Methods

A systematic review from potentially relevant published articles reporting contralateral deep vein thrombosis after iliac venous stenting between January 2007 and February 2019 was performed.

Results

A total of 764 references were retrieved initially. Twelve studies reporting events of contralateral deep vein thrombosis were selected for review, with a total of 1864 patients. Contralateral deep vein thrombosis incidence varied between 0% and 15.6%. The post-interventional and follow-up anticoagulation regimens were heterogeneous between studies. The decision to maintain patients on anticoagulation and the duration of treatment was based on the presence of comorbidities, hypercoagulable states, post-thrombotic syndrome and history of recurrent deep vein thrombosis. Patients with non-thrombotic iliac vein lesions were either anticoagulated for three or six months after stenting or received no anticoagulation. Patients with post-thrombotic syndrome were anticoagulated for longer periods. Most studies (eight studies) used an oral vitamin K antagonist agent. The data on compliance with anticoagulation treatment is scarce and few references present data on whether contralateral deep vein thrombosis occurred during anticoagulation treatment. The use of antiplatelet agents in addition to the anticoagulant treatment in the follow-up period was also variable.

Conclusion

The incidence of contralateral deep vein thrombosis due to iliac vein jailing is not negligible and reported being as high as 15.6%. Large-scale studies on the ideal antithrombotic treatment and its impact are necessary. It is possible that patients with stent crossing the iliocaval confluence might benefit from long-term antithrombotic treatment.

Keywords

Iliac veins complications postoperative stent contralateral deep vein thrombosis chronic venous disease

Get full access to this article

View all access options for this article.

References

Taha

Busuttil

Bootun

A systematic review on the use of deep venous stenting for acute venous thrombosis of the lower limb.

Phlebology 2019; 34: 115–127.

Delis

Bjarnason

Wennberg

PW.

Successful iliac vein and inferior vena cava stenting ameliorates venous claudication and improves venous outflow, calf muscle pump function, and clinical status in post-thrombotic syndrome.

Ann Surg 2007; 245: 130–139.

Tosenovsky

One-year results of iliocaval stenting. Ann Vasc Surg 2019; 59: 208–216.

Seager

Busuttil

Dharmarajah

Editor’s choice – a systematic review of endovenous stenting in chronic venous disease secondary to iliac vein obstruction.

Eur J Vasc Endovasc Surg 2016; 51: 100–120.

Neglen

Darcey

Olivier

Bilateral stenting at the iliocaval confluence.

J Vasc Surg 2010; 51: 1457–1466.

Gloviczki

Lawrence

PF.

Iliac vein stenting and contralateral deep vein thrombosis.

J Vasc Surg Venous Lymphat Disord 2017; 5: 5–6.

Rathore

Gloviczki

Bjarnason

Open surgical removal of iliac vein Wallstents with excision of pseudointima obstructing the contralateral iliac vein.

J Vasc Surg Venous Lymph Disord 2016; 4: 525–529.

Raju

Neglen

Percutaneous recanalization of total occlusions of the iliac vein.

J Vasc Surg 2009; 50: 360–368.

Avgerinos

Hager

Naddaf

Outcomes and predictors of failure of thrombolysis for iliofemoral deep venous thrombosis.

J Vasc Surg Venous Lymphat Dis 2015; 3: 35–41.

10.

Khairy

Neves

Hartung

Factors associated with contralateral deep venous thrombosis after iliocaval venous stenting. Eur J Vasc Endovasc Surg 2017; 54: 745–751.

11.

Moher

Liberati

Tetzlaff

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Int J Surg 2010; 8: 336–341.

12.

Koelemay

Vermeulen

Quick guide to systematic reviews and meta-analysis.

Eur J Vasc Endovasc Surg 2016; 51: 309.

13.

Raju

Neglen

High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: a permissive role in pathogenicity.

J Vasc Surg 2006; 44: 136–143; discussion 44.

14.

Baldwin

Moore

Rudarakanchana

Post-thrombotic syndrome: a clinical review.

J Thromb Haemost 2013; 11: 795–805.

15.

Liu

Gao

Shen

Endovascular treatment for symptomatic iliac vein compression syndrome: a prospective consecutive series of 48 patients.

Ann Vasc Surg 2014; 28: 695–704.

16.

Caliste

Clark

Doyle

AJ.

The incidence of contralateral iliac venous thrombosis after stenting across the iliocaval confluence in patients with acute or chronic venous outflow obstruction.

J Vasc Surg Venous Lymphat Disord 2014; 2: 253–259.

17.

Park

Ahn

Jeon

YS.

Iliac vein stenting as a durable option for residual stenosis after catheter-directed thrombolysis and angioplasty of iliofemoral deep vein thrombosis secondary to May–Thurner syndrome.

Phlebology 2014; 29: 461–470.

18.

Murphy

Johns

Varney

Deep venous thrombosis associated with caval extension of iliac stents.

J Vasc Surg Venous Lymphat Disord 2017; 5: 8–17.

19.

van Vuuren

Doganci

Wittens

CHA.

Patency rates and clinical outcomes in a cohort of 200 patients treated with a dedicated venous stent.

J Vasc Surg Venous Lymphat Disord 2018; 6: 321–329.

20.

Lee

Park

KM.

Contralateral deep vein thrombosis after iliac vein stent placement in patients with May–Thurner syndrome.

J Vasc Interv Radiol 2018; 29: 774–780.

21.

Rossi

Kambara

Izukawa

NM.

Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease.

J Vasc Surg Venous Lymphat Disord 2018; 6: 183–191.

22.

Sang

XL.

Diagnosis and endovascular treatment of iliac venous compression syndrome. Phlebology 2019; 34: 40–51.

23.

Zhang

Jing

Sang

Long-term follow-up of the stenting across the iliocaval confluence in patients with iliac venous lesions.

J Thromb Thrombolysis 2019; 47: 134–139.

24.

Yuan

Zhu

Endovascular treatment for iliofemoral vein thrombosis with composite stents.

Ann Vasc Surg 2018; 51: 262–268.

25.

Gagne

Kucher

Long-term clinical outcomes and technical factors with the Wallstent for treatment of chronic iliofemoral venous obstruction.

J Vasc Surg Venous Lymphat Disord 2019; 7: 45–55.

26.

Raju

Ward

Jr Kirk

A modification of iliac vein stent technique.

Ann Vasc Surg 2014; 28: 1485–1492.

27.

de Graaf

de Wolf

Sailer

AM.

Iliocaval confluence stenting for chronic venous obstructions.

Cardiovasc Intervent Radiol 2015; 38: 1198–1204.

28.

Stuck

Kunz

Baumgartner

Patency and clinical outcomes of a dedicated, self-expanding, hybrid oblique stent used in the treatment of common iliac vein compression.

J Endovasc Ther 2017; 24: 159–166.

29.

Milinis

Thapar

Shalhoub

Antithrombotic therapy following venous stenting: international Delphi consensus.

Eur J Vasc Endovasc Surg 2018; 55: 537–544.

30.

Wittens

Davies

Baekgaard

Editor’s choice – management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015; 49: 678–737.

31.

Kearon

Akl

Ornelas

Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.

Chest 2016; 149: 315–352.

Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease – A systematic review

Abstract

Objective

Methods

Results

Conclusion

Keywords

Get full access to this article

References